Market Research Logo

Global Lymphoma Drugs Market 2017-2021

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
    • Lymphoma disease overview
      • Table Types of lymphoma
      • Table Tests for lymphoma
      • Table Stages of lymphoma development
      • Table Treatment options for lymphoma
  • Market Introduction
    • Market overview
      • Table Global lymphoma drugs market snapshot
    • Market size and forecast
      • Table Global lymphoma drugs market 2016-2021($ millions)
      • Table Opportunity analysis in global lymphoma drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Key pipeline drugs by vendors
    • Table Pipeline analysis
  • Market segmentation by disease type
    • Table Segmentation of global lymphoma drugs market by disease type 2016
    • Table Market share of global lymphoma drugs market based on disease type 2016 and 2021
    • HL
      • Table Subtypes of HL
      • Table Types of classic HL
      • Table Global HL drugs market 2016-2021 ($ millions)
      • Table Major drugs involved in HL drugs market
    • NHL
      • Table Types of NHL
      • Table Prevalence of various B-cell lymphoma in NHL
      • Table T-cell and natural killer cell lymphoma types
      • Table Global NHL drugs market 2016-2021 ($ millions)
      • Table Key highlights of NHL drugs market
  • Geographical segmentation
    • Table Segmentation of global lymphoma drugs market based on geography 2016 and 2021
    • Table Global lymphoma drugs market revenue by geography 2016-2021 ($ millions)
    • Lymphoma drugs market in Americas
      • Table Market scenario in Americas
      • Table Lymphoma drugs market in Americas 2016-2021 ($ millions)
      • Table Incidence of NHL in Americas
    • Lymphoma drugs market in EMEA
      • Table Market scenario in EMEA
      • Table Lymphoma drugs market in EMEA 2016-2021 ($ millions)
      • Table Lymphoma cases in UK 2014
      • Table Incidence of NHL in EMEA
    • Lymphoma drugs market in APAC
      • Table Market scenario in APAC
      • Table Lymphoma drugs market in APAC 2016-2021 ($ millions)
      • Table Incidence of NHL in APAC
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Grants for research projects for NHL compared with total cancer researches 2016
    • Market challenges
      • Table Drugs and associated side effects
  • Market trends
    • Increasing consolidation in the cancer treatment market
    • Development of rituximab resistance leading to the development of new therapies
    • Studies performed to understand the genetics of lymphoma cells
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global lymphoma drugs market 2016
      • Table Strategic success factors of companies in global lymphoma drugs market
  • Key vendor analysis
    • Celgene
      • Table Celgene: Key highlights
      • Table Celgene: Strength assessment
      • Table Celgene: Strategy assessment
      • Table Celgene: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Johnson & Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Seattle Genetics
      • Table Seattle Genetics: Key highlights
      • Table Seattle Genetics: Strength assessment
      • Table Seattle Genetics: Strategy assessment
      • Table Seattle Genetics: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Global Lymphoma Drugs Market 2017-2021

About Lymphoma Drugs

Lymphoma is a type of cancer that affects the immune system of the body. Specifically, it affects the lymphocytes, a type of white blood cell. The lymphocytes are part of the immune system and help the body to fight infections. The cancerous lymphocytes grow uncontrollably and collect in different portions of the body; lymph node can be one of the most common sites for lymphoma development. The lymph nodes are found throughout the body particularly in the groin, neck, and under the arms. Lymphoma can also develop in the deeper lymph nodes such as those in bone marrow and spleen. Very rarely this disease can start in other parts of the body such as stomach, breast, skin, brain, bowel, or liver.

Technavio’s analysts forecast the global lymphoma drugs market to grow at a CAGR of 8.02% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global lymphoma drugs market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Lymphoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Celgene
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • Seattle Genetics
Other prominent vendors
  • Amgen
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
Market driver
  • Increase in industry-academia collaborations
  • For a full, detailed list, view our report
Market challenge
  • High cost of lymphoma treatment
  • For a full, detailed list, view our report
Market trend
  • Increasing consolidation in the cancer treatment market
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Lymphoma Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global lymphoma drugs market: Celgene, F. Hoffmann-La Roche, Johnson & Johnson, and Seattle Genetics.

Other Prominent Vendors in the market are: Amgen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Takeda Pharmaceuticals, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is increasing consolidation in the cancer treatment market. Past several years have witnessed significant consolidation in the cancer treatment industry. There can be seen a trend of movement of cancer treatment from clinics to hospitals. Studies have shown that there is a rise in a number of oncology clinics that got acquired by hospitals.”

According to the report, one of the major drivers for this market is increase in industry-academia collaborations. The key players in the market are increasingly extending their support to academic institutions to support the R&D of innovative drugs. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharmaceutical companies, besides providing funds to conduct trial studies. For instance, Merck's cancer segment collaborated with academic institutions such as BioMed X to support R&D activities in the development of monoclonal antibodies (mAbs) for cancer segment.

Further, the report states that one of the major factors hindering the growth of this market is high cost of lymphoma treatment. The high cost of treatment is a major problem for the lymphoma patients across the globe. Many of the treatment options available for the individuals are out of their budget and ultimately forces the individual or the payer to skip the treatment. Virtual monopoly among the drug manufacturers and the high cost of R&D are some of the major factors for the high cost of lymphoma treatment. A large proportion of population either skip the treatment or leave it in the middle. Despite availing the costly treatment, reoccurrence of the disease quadruples the issues and negatively affects the patient adherence.



Companies Mentioned

Celgene, F. Hoffmann-La Roche, Johnson & Johnson, Seattle Genetics, Amgen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Takeda Pharmaceuticals, and Teva Pharmaceutical Industries.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;